PepGenexShop our research products

CJC-1295 (no DAC)

Also identified as Modified GRF (1-29), CJC-1295 without DAC, Mod GRF 1-29

Growth-hormone-releasing hormone analogue without drug affinity complex

Published studies reviewed
2

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.

Compounds described on this site are supplied solely for laboratory research. They are not offered for human or veterinary use or for clinical use, and they are not intended to diagnose, mitigate, cure or prevent any disease.

This page covers CJC-1295 without the drug affinity complex, also printed as modified GRF (1-29): the growth-hormone-releasing hormone analogue lacking the maleimide group that lets the conjugated form attach to albumin. The publications reviewed are analytical chemistry, among them a forensic identification of seized powders and a detection-method study that found the peptide intact in rat plasma. None measured a hormone response, pharmacokinetics or safety, and the conjugated form's human data, recorded on the separate CJC-1295 page, do not carry over.

At a glance

Also identified as
Modified GRF (1-29), CJC-1295 without DAC, Mod GRF 1-29
Class
Growth-hormone-releasing hormone analogue without drug affinity complex
Evidence types represented
in vitro, animal
Published studies reviewed
2
Last reviewed
2026-09-26

Overview

CJC-1295 without the drug affinity complex — the literature also prints it as modified GRF (1-29) — is the analogue of growth-hormone-releasing hormone without the maleimide group that makes the conjugated form attach to albumin and persist in circulation.

The two forms are not interchangeable, and this page is short for a reason. The published human study of CJC-1295, with its half-life of 5.8 to 8.1 days, used the DAC-conjugated form and is recorded on the CJC-1295 page. That half-life is a property of the conjugation. Nothing on that page transfers here.

Searching for this material itself turns up analytical chemistry: a study of how it breaks down in vitro and how it can be detected in urine, forensic identifications of powders seized at borders, and a detection-method study in which it was given to rats and found intact in their plasma for up to 8 hours.

That rat study is the only record this project found of the material being given to a living animal, and it measured whether the peptide could be detected, not what it did. No publication identified here recorded a hormone response, a pharmacokinetic parameter or a safety finding in an animal or a person. That is the state of the literature as of September 2026, not a gap in what has been collected.

Scope of the published work

Areas investigated
  • In-vitro metabolism
  • Detection in urine
  • Identification of seized material
  • Detection in plasma
Models used
  • Fortified urine
  • Seized powders
  • Rats (detection in plasma)

The publications on this page are analytical chemistry. One detected the material in rat plasma after it was given to rats; none measured a hormone response, pharmacokinetics or safety in an animal or a person, so nothing here describes what the material does in a living system, and no figure on this page is a statement about the research material PepGenex supplies.

Limitations

Evidence represented on this page: in vitro and animal. No human research is represented. The page reviews 2 published studies, and each figure is reported for the study that published it; results are not pooled across studies. 1 of these publications carries a note on whether it studied this exact material.

Common questions

What is CJC-1295 (no DAC)?

CJC-1295 without the drug affinity complex — the literature also prints it as modified GRF (1-29) — is the analogue of growth-hormone-releasing hormone without the maleimide group that makes the conjugated form attach to albumin and persist in circulation.

What has published research on CJC-1295 (no DAC) found, and what are its limits?

This page records 2 publications, reporting laboratory (in vitro) work in 2, animal work in 1. Each is listed with its identifier under References.

No human study is represented on this page.

Evidence represented on this page: in vitro and animal.

No human research is represented.

The page reviews 2 published studies, and each figure is reported for the study that published it; results are not pooled across studies.

1 of these publications carries a note on whether it studied this exact material.

The publications on this page are analytical chemistry. One detected the material in rat plasma after it was given to rats; none measured a hormone response, pharmacokinetics or safety in an animal or a person, so nothing here describes what the material does in a living system, and no figure on this page is a statement about the research material PepGenex supplies.

Is CJC-1295 (no DAC) approved by the U.S. FDA?

This page cites no FDA approval record for CJC-1295 (no DAC); PepGenex Science states a U.S. regulatory status only where a sourced record exists.

PepGenex research materials are not FDA approved and are not for human or veterinary use.

What risks have published studies of CJC-1295 (no DAC) reported?

No human study is recorded on this page, so it reports no adverse events in people. Laboratory and animal findings are not a measure of risk in people.

Published research

Grouped by the kind of study. Select one to narrow what is shown below.

Laboratory (in vitro)(1)

Laboratory (in vitro)

Glycine-modified growth hormone secretagogues identified in seized doping material.

Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, Dalsgaard PW, Reitzel LA, Linnet K., Drug Testing and Analysis, 2019;11(2):350-354

published

Material identity not established. The compound identified in these powders was modified GRF (1-29) carrying an EXTRA glycine at its N-terminus — a glycine-extended variant, not the unextended peptide. It is recorded here because the powders were sold as this material; the finding is about what was in them.

  • Unknown pharmaceutical preparations seized by Danish customs authorities were analysed by liquid chromatography–high resolution mass spectrometry and compared with reference standards. The contents of the powders were identified as analogues of the growth-hormone secretagogues GHRP-2 (pralmorelin), GHRP-6 and ipamorelin, and of modified growth-hormone releasing factor, modified GRF (1-29).
  • In all cases the detected modification involved the addition of an extra glycine amino acid at the N-terminus, and the authors state that analytical methods targeting growth-hormone secretagogues should be updated accordingly.
Context

The forensic study is worth reading for what it says about supply rather than about pharmacology: every powder examined carried an extra glycine on the front of the peptide. A material sold under a name is not necessarily that material, and in this seizure none of the four substances examined was exactly what its name implied.

View publication →

Preclinical (animal)(1)

Laboratory (in vitro)Preclinical (animal)

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M., Analytical and Bioanalytical Chemistry, 2016;408(12):3145-3153

published

Develops and validates a method for detecting four growth-hormone-releasing hormones — sermorelin, CJC-1293, CJC-1295 and tesamorelin — and two metabolites in human plasma, using immunoaffinity purification with a polyclonal GHRH antibody followed by nano-ultrahigh performance liquid chromatography with high-resolution mass spectrometry. The validation figures are reported for the analytes together: recovery of 19–37%, a lower limit of detection below 50 pg/mL, and imprecision below 20%.

  • The publication identifies the material it calls CJC-1295 by sequence, as (D-Ala2, Gln8, Ala15, Leu27)-GRF amide: a 29-residue amidated analogue of growth-hormone-releasing factor that differs from sermorelin, listed in the same table, at four positions and carries no lysine extension or maleimide group. It was custom-synthesised for the study.
  • Each of the four peptides was given to Wistar rats, and blood was sampled 2, 4 and 8 hours afterwards. CJC-1295 was detected intact in rat plasma at every sampling time, the 8-hour sample being the last collected, and no anticipated metabolite of it was found. The authors state that only qualitative results were obtained and that no pharmacokinetic interpretation was made.
  • In the rats, sermorelin and CJC-1293 were readily biotransformed compared with CJC-1295. The authors attribute the absence of N-terminally truncated metabolites of CJC-1293 and CJC-1295 to their D-alanine at position 2, and report that both remained detectable intact up to the last sampling time.
  • The rat work recorded whether the peptide could be found in plasma, not what it did. No growth hormone or IGF-I concentration, pharmacokinetic parameter or adverse event was reported for the animals, the number of animals per compound is not stated consistently, and the authors call for further studies of species-related differences in metabolism and elimination.
Limitations

The record for this material is analytical, and that is the finding. Three laboratories worked out how to recognise it — in urine, in rat plasma, and in powders seized at a border — and no publication this project could find has measured a response to it in an animal or a person. The figures that circulate under the name CJC-1295 come from studies of the DAC-conjugated form, which is a different molecule; they are on that compound's page and they do not carry over.

View publication →

Compared with related compounds

Classification, structure, recorded targets, evidence types and FDA status only, each read from the two compounds' own pages. These comparisons do not compare study results.

CJC-1295 (no DAC) and CJC-1295

The same growth-hormone-releasing hormone analogue class; the two are distinct molecules.

CJC-1295 (no DAC)CJC-1295
ClassificationGrowth-hormone-releasing hormone analogue without drug affinity complexGrowth-hormone-releasing hormone analogue
StructureNot recorded on its pageFormula C165H269N47O46
Targets recordedNo target recorded on its pageAgonist: Growth-hormone-releasing hormone receptor
Evidence types representedin vitro, animalin vitro, animal, human
Status with the U.S. FDANot shown (no Drugs@FDA application record verified for this page)Not shown (no Drugs@FDA application record verified for this page)

CJC-1295 (no DAC) and Sermorelin

Growth-hormone-releasing hormone analogues.

CJC-1295 (no DAC)Sermorelin
ClassificationGrowth-hormone-releasing hormone analogue without drug affinity complexGrowth-hormone-releasing hormone analogue, GHRH (1-29)
StructureNot recorded on its pageSequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; formula C149H246N44O42S
Targets recordedNo target recorded on its pageAgonist: Growth-hormone-releasing hormone receptor
Evidence types representedin vitro, animalin vitro, human
Status with the U.S. FDANot shown (no Drugs@FDA application record verified for this page)Drugs@FDA lists two approved applications for sermorelin acetate, and the products under both are listed as discontinued. Source: Drugs@FDA, Applications NDA 019863 and NDA 020443.

CJC-1295 (no DAC) and Tesamorelin

Growth-hormone-releasing hormone analogues.

CJC-1295 (no DAC)Tesamorelin
ClassificationGrowth-hormone-releasing hormone analogue without drug affinity complexGrowth-hormone-releasing hormone analogue
StructureNot recorded on its pageFormula C221H366N72O67S
Targets recordedNo target recorded on its pageAgonist: Growth-hormone-releasing hormone receptor
Evidence types representedin vitro, animalhuman
Status with the U.S. FDANot shown (no Drugs@FDA application record verified for this page)An FDA approved drug product containing tesamorelin exists. Source: Drugs@FDA, Application BLA 022505.

References

Published studies reviewed (2)

  1. Glycine-modified growth hormone secretagogues identified in seized doping material. — Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, Dalsgaard PW, Reitzel LA, Linnet K., Drug Testing and Analysis, 2019;11(2):350-354
    DOI 10.1002/dta.2489 · PMID 30136411
  2. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. — Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M., Analytical and Bioanalytical Chemistry, 2016;408(12):3145-3153
    DOI 10.1007/s00216-016-9377-3 · PMID 26879649 · PMC4830873

Continue learning